Tabrecta Disease Interactions

Capmatinib is primarily metabolized by CYP450 3A4 and aldehyde oxidase and its use may cause hepatotoxicity. Assess liver function tests, including ALT, AST, and total bilirubin before administering capmatinib, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Caution when using this agent in patients with liver disorder or a disorder of bilirubin metabolism. Withhold, reduce the dose, or permanently discontinue capmatinib based on severity of adverse reactions. No clinically significant effects on the pharmacokinetic parameters of capmatinib were identified in patients with mild, moderate or severe hepatic impairment.

The use of capmatinib may cause interstitial lung disease (ILD)/pneumonitis. Exercise care when using this agent in patients with disorders of the lung. It is recommended to monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Immediately withhold treatment with capmatinib in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are identified.

The use of capmatinib may cause photosensitivity reactions. Exercise care when using this agent in patients predisposed to photosensitivity reactions or with a history of skin cancer. It is recommended that patients use precautionary measures against ultraviolet exposure such as use of sunscreen or protective clothing during treatment with capmatinib. Advise patients to limit direct ultraviolet exposure during treatment.

No clinically significant effects on the pharmacokinetic parameters of capmatinib were identified in patients with mild to moderate renal impairment. Therefore, no dosage adjustment is recommended in patients with mild or moderate renal impairment. Exercise care when using capmatinib in patients with severe renal impairment as it has not been studied in these patient population.